Group items tagged

Head injuries are a serious matter. They can lead to long-term health problems and even death in some cases. This article will go over some unexpected scenarios that often lead to head injuries. AIRBAG DEPLOYMENT Car accidents occur often, and you probably think you're safe from minor ones if you have your seatbelt strapped in. However, many people have suffered airbag injuries from a car accident because of their position at the moment it deployed. This may not seem like a big deal, but airbags inflate quickly, at around 200 miles per hour, and with great force. If your head is too close to the airbag when it deploys, you can suffer from some serious injuries. So what can you do to avoid this? First, make sure that you're sitting in an upright position with plenty of space between you and the steering wheel. Additionally, try to keep your headrest in an upright position so that it can provide some support if an accident does occur. And finally, be aware of airbag deployment times; they typically deploy within 0.08-0.14 seconds after an impact occurs.

The Department of Health and Social Care (DHSC) and the Medicines and Healthcare Products Regulatory Agency (MHRA) have added five more medicines that cannot be hoarded or exported from the UK market. The government has taken the following action to address the "critical shortage" of attention deficit hyperactivity disorder (ADHD) drugs. In a crucial development on October 9, this strategic move aims to enable wholesalers to fulfil their legal obligation to supply these essential medicines to patients across the UK. The updated list of drugs incorporated "all" available strengths and pharmaceutical formulations, ensuring comprehensive coverage for patients' medical needs.

Pendle MP Andrew Stephenson has been appointed as a Minister of State in the Department of Health and Social Care (DHSC) in the latest ministerial reshuffle. As the new 'Minister for Health and Secondary Care', Stephenson would be looking after elective care recovery and screening, as well as the fight against major diseases like cancer, diabetes and stroke, as reported by Burnley Express. "Helping NHS services recover from the legacy of the pandemic, whilst dealing with winter pressures and the challenges of inflation will not be easy, but it is a challenge I am looking forward to," Stephenson told Burnley Express. "I am also keen to ensure that significant manifesto commitments, such as the pledge to deliver 50,000 nurses and 40 new hospitals remain on track. Especially as one of those 40 new hospitals is Airedale, which is used by so many Colne and West Craven residents," he added.

MedAdvisor will be investing $1.9 million (£1 million) into UK-based pharmacy dispensary app Charac, while securing a 7.4 per cent shareholding in the later company. Under this new agreement, MedAdvisor CEO Rick Ratliff will become a Non-Executive Director (NED) on the board of Charac. Both MedAdvisor and Charac provide digital medication adherence solutions that allow customers to file prescription orders to their local pharmacy through mobile apps. The investment is seen as part of MedAdvisor's cost saving strategy, as the Australian company has decided to discontinue its UK operations, and transfer its existing pharmacy relationships to Charac.

The Federation of Small Businesses (FSB) on Thursday (4 December) announced a new strategic partnership with the Bank of England to protect small businesses from the risks associated with accepting counterfeit banknotes. Cash is still the number one customer payment method for 25 per cent of small high street businesses, and cash payments are expected to increase during the festive period, according to FSB. By becoming a Strategic Partner of the Bank of England's Banknote Checking Scheme, the organisation is trying to help its members become aware of the use of counterfeit notes, which has reputational and financial impacts. The FSB is encouraging its members to sign up to the Scheme, which offers training materials to staff so they can identify a counterfeit note at point of sale and know what to do with it, as well as stay up to date with best practice and bank note developments.

Generic and over-the-counter drugs company Stada has asked the German government to seek assurances from Ukraine that the company can continue operations there even though it also does business in Russia. In a March 21 letter to German Economy Minister Robert Habeck, Stada CEO Peter Goldschmidt said there was a risk Kyiv might withdraw the company's market authorisation. Stada "still has no longer-term certainty that we will be able to sell our products in Ukraine in the future," the letter said, with the subject line: "Please prevent the exclusion of international pharmaceutical companies from the Ukrainian market." The Economy Ministry did not have an immediate comment on the letter. Habeck promised investment guarantees for German companies during a trip to Ukraine on Tuesday (April 4) as part of his goal to speed up reconstruction in the war-torn country. Goldschmidt said restricting Stada's operations would be bad for Ukraine.

Medical professionals often prescribe semaglutide to patients who have type 2 diabetes. Along with a balanced diet and regular exercise, it has also shown to be an incredibly efficient weight loss aid for patients. As the active ingredient in well-known brand-name drugs such as Wegovy, Ozempic, and Rybelsus, semaglutide is currently on everybody's lips. But what exactly is semaglutide? Does it really work for weight loss? We'll find an answer for you in this article, and explain the main benefits of using semaglutide for weight loss. What Is Semaglutide? A number of diabetic and weight loss medications, including Wegovy, Ozempic, and Rybelsus, have semaglutide as their active ingredient. This substance is a synthetic form of the hormone glucagon-like peptide-1 (GLP-1), that occurs naturally. Developed by the company Novo Nordisk, semaglutide was first approved by the FDA in 2017 as an injection for the treatment of adult type 2 diabetes (as part of the approval procedure for Ozempic). In 2019, the Food and Drug Administration approved a novel semaglutide form known as Rybelsus. Rybelsus was the first oral GLP-1 receptor agonist for the treatment of type 2 diabetes in the United States.

Erectile dysfunction (ED), also known as impotence, is characterized by the consistent or recurrent inability to achieve and/or maintain an erection sufficient for sexual intercourse. It becomes increasingly common with age, affecting approximately 50 - 55 per cent of men aged between 40 and 70 years. ED is estimated to affect up to three-quarters of men globally, and by 2025, 322 million men are expected to experience it. Research indicates that erectile dysfunction is highly prevalent in the UK, affecting over a quarter of younger men. Among Brits with ED, cardiometabolic and psychological conditions were frequently observed. Despite the high prevalence of erectile dysfunction among men, it remains poorly understood, underdiagnosed, and undertreated.